Studiedetails

Type carcinoma: NSCLC met mutatie
Stadium:
Mutatie: CAE-CAM5 (wordt in prescreening bepaald)
Lijn: 2de/3de
Site: Erasmus MC & Amphia
Contactgegevens:

long.oncologie@erasmusmc.nl
researchlongoncologie@amphia.nl
Website:

 Inclusiecriteria

– Histologically or cytologically proven diagnosis of non-squamous NSCLC metastatic disease
– Progressive disease during or after platinum-based chemotherapy (at least 2 cycles).
– Having progressive disease during or after one immune checkpoint inhibitor
– Participant with EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations must be able to demonstrate progression of the disease on approved treatments for these conditions
– (ECOG) performance status 0-1

 Exclusiecriteria

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie: